ArticleTheranostics2022

A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.

Dong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.